Search Results

There are 3324428 results for: content related to: The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

  1. You have free access to this content
    Nilotinib, imatinib, and telomere homeostasis disruption in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 20, 15 October 2012, Page: 5183, Franck E. Nicolini, Paul W. Manley and Tim H. Brümmendorf

    Version of Record online : 25 APR 2012, DOI: 10.1002/cncr.27481

  2. You have free access to this content
    Reply to the prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia

    Cancer

    Volume 118, Issue 20, 15 October 2012, Page: 5180, Susan O'Brien

    Version of Record online : 17 APR 2012, DOI: 10.1002/cncr.27524

  3. You have free access to this content
    Nilotinib versus imatinib

    Cancer

    Volume 118, Issue 20, 15 October 2012, Pages: 5181–5182, Rumiana Bakalova, Zhivko Zhelev and Lubomir Spasov

    Version of Record online : 25 APR 2012, DOI: 10.1002/cncr.27479

  4. You have free access to this content
    Expanding Nilotinib Access in Clinical Trials (ENACT)

    Cancer

    Volume 118, Issue 1, 1 January 2012, Pages: 118–126, Franck E. Nicolini, Anna Turkina, Zhi-Xiang Shen, Neil Gallagher, Saengsuree Jootar, Bayard L. Powell, Carmino De Souza, Ming Zheng, Tomasz Szczudlo and Philipp le Coutre

    Version of Record online : 5 JUL 2011, DOI: 10.1002/cncr.26249

  5. Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam

    The Journal of Clinical Pharmacology

    Volume 55, Issue 4, April 2015, Pages: 401–408, Hefei Zhang, Jennifer Sheng, Jin H. Ko, Cheng Zheng, Wei Zhou, Petra Priess, Wen Lin and Steven Novick

    Version of Record online : 27 FEB 2015, DOI: 10.1002/jcph.434

  6. Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: An insight

    Clinical and Experimental Pharmacology and Physiology

    Volume 41, Issue 10, October 2014, Pages: 788–797, Gamal E Shiha, Nashwa M Abu-Elsaad, Khaled R Zalata and Tarek M Ibrahim

    Version of Record online : 30 OCT 2014, DOI: 10.1111/1440-1681.12286

  7. Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 51, Issue 1, January 2011, Pages: 75–83, Dr Chiaki Tanaka, Dr Ophelia Q. P. Yin, Dr Tom Smith, Dr Venkat Sethuraman, Ms Karen Grouss, Dr Lawrence Galitz, Dr Robert Harrell and Dr Horst Schran

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010367428

  8. Effects of Yogurt and Applesauce on the Oral Bioavailability of Nilotinib in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 51, Issue 11, November 2011, Pages: 1580–1586, Dr Ophelia Q. P. Yin, Dr Marc Rudoltz, Dr Ivana Galetic, Dr Jeiry Filian, Dr Arun Krishna, Dr Wei Zhou, Dr Joseph Custodio, Dr Georg Golor and Dr Horst Schran

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010384116

  9. You have free access to this content
    Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy

    Cancer

    Volume 118, Issue 21, 1 November 2012, Pages: 5265–5269, Marzia Defina, Micaela Ippoliti, Alessandro Gozzetti, Elisabetta Abruzzese, Fausto Castagnetti, Rosaria Crupi, Mario Tiribelli, Massimo Breccia, Marzia Salvucci, Lara Aprile, Claudia Baratè, Antonella Gozzini, Gianantonio Rosti, Francesco Lauria and Monica Bocchia

    Version of Record online : 19 APR 2012, DOI: 10.1002/cncr.27506

  10. You have free access to this content
    Practical management of patients with chronic myeloid leukemia

    Cancer

    Volume 117, Issue 19, 1 October 2011, Pages: 4343–4354, Francisco Cervantes and Michael Mauro

    Version of Record online : 16 MAR 2011, DOI: 10.1002/cncr.26062

  11. Effect of Grapefruit Juice on the Pharmacokinetics of Nilotinib in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 50, Issue 2, February 2010, Pages: 188–194, Dr Ophelia Q. P. Yin, Dr Neil Gallagher, Dr Ai Li, Dr Wei Zhou, Dr Robert Harrell and Dr Horst Schran

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009336137

  12. You have full text access to this OnlineOpen article
    Suboptimal responses in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 5, 1 March 2012, Pages: 1181–1191, Elias Jabbour, Giuseppe Saglio, Timothy P. Hughes and Hagop Kantarjian

    Version of Record online : 28 OCT 2011, DOI: 10.1002/cncr.26391

  13. Effect of the Proton Pump Inhibitor Esomeprazole on the Oral Absorption and Pharmacokinetics of Nilotinib

    The Journal of Clinical Pharmacology

    Volume 50, Issue 8, August 2010, Pages: 960–967, Dr Ophelia Q. P. Yin, Dr Neil Gallagher, Dr Deirdre Fischer, Dr Eren Demirhan, Dr Wei Zhou, Dr Georg Golor and Dr Horst Schran

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270009346061

  14. Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 2, February 2010, Pages: 197–203, C Tanaka, O Q P Yin, V Sethuraman, T Smith, X Wang, K Grouss, H Kantarjian, F Giles, O G Ottmann, L Galitz and H Schran

    Version of Record online : 18 NOV 2009, DOI: 10.1038/clpt.2009.208

  15. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

    Biopharmaceutics & Drug Disposition

    Volume 33, Issue 9, December 2012, Pages: 536–549, Binfeng Xia, Tycho Heimbach, Handan He and Tsu-han Lin

    Version of Record online : 19 NOV 2012, DOI: 10.1002/bdd.1821

  16. High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma

    Biomedical Chromatography

    Volume 24, Issue 7, July 2010, Pages: 789–793, Masatomo Miura, Naoto Takahashi and Ken-ichi Sawada

    Version of Record online : 10 NOV 2009, DOI: 10.1002/bmc.1364

  17. Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib

    Clinical Pharmacology & Therapeutics

    Volume 95, Issue 3, March 2014, Pages: 294–306, L N Eadie, T P Hughes and D L White

    Version of Record online : 9 OCT 2013, DOI: 10.1038/clpt.2013.208

  18. Are nilotinib-associated vascular adverse events an under-estimated problem?

    Fundamental & Clinical Pharmacology

    Volume 29, Issue 2, April 2015, Pages: 204–208, Marie Stève-Dumont, Bernadette Baldin, Laurence Legros, Antoine Thyss, Daniel Re, Fanny Rocher, Florian Ajmia, Anne Spreux and Milou-Daniel Drici

    Version of Record online : 11 MAR 2015, DOI: 10.1111/fcp.12102

  19. You have free access to this content
    Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia

    Cancer

    Volume 118, Issue 2, 15 January 2012, Pages: 300–311, Jerald P. Radich

    Version of Record online : 29 JUN 2011, DOI: 10.1002/cncr.26280

  20. You have full text access to this Open Access content
    Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling

    Journal of Cellular and Molecular Medicine

    Volume 12, Issue 5b, October 2008, Pages: 2107–2118, J. Chen, A. Schmitt, B. Chen, M. Rojewski, V. RuBeler, F. Fei, Y. Yu, X. Yu, M. Ringhoffer, S. von Harsdorf, J. Greiner, M. Gbtzz, P. Guillaume, H. Dbhner, D. Bunjes and M. Schmitt

    Version of Record online : 11 JAN 2008, DOI: 10.1111/j.1582-4934.2008.00234.x